Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 3Neuroendocrine Tumors 1Hypoxia 1

Interventions

3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 4pimonidazole 2TH 302 2pembrolizumab 1inositol trispyrophosphate 1gadobutrol 1fluoromisonidazole 1Tirapazamine 1Surgical Procedures, Operative 1Radiotherapy 1Propofol 1Pancreaticoduodenectomy 1Paclitaxel 1Ipilimumab 1Injections 1Gemcitabine 1Ethiodized Oil 1Cisplatin 1Blood Specimen Collection 1Biopsy 1AQ4N 14-methylbenzenesulfonic acid 13-(4-(2-fluoroethoxy)phenyl)-2-(3-methyl-2-(4-((2-sulfamoylbenzo(d)thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypoxia × Tirapazamine × Gastrointestinal × Clear all
NCT02174549 2026-04-20

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Teclison Ltd.

Phase 1/2 Recruiting
25 enrolled
EndocrineGastrointestinalNET

Hypoxia, Carcinoma, Hepatocellular, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡